Skip to main navigation

Search for:

CytomX

Search for:

About
Probody Therapeutics
Pipeline
Partners
- Opportunities
- Current Partners
Investors & News
Culture & Careers

Menu

Xciting things are happening here

Press Releases

Press Releases

Year

January 19, 2021

CytomX Therapeutics Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif. , Jan. 19, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced that on

Additional Formats

PDF Version

January 7, 2021

CytomX Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , Jan. 07, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced that

Additional Formats

PDF Version

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 12 of 12

Corporate Profile
Press Releases
Events and Presentations
Scientific Publications
Corporate Governance
Stock Information
Financials & Filings
Analyst Coverage
Investor Resources

Investor Tools
Print Page
Email Page
RSS Feeds
Email Alerts
Contact IR

Contact Us

151 Oyster Point Blvd, Suite 400

South San Francisco, CA

94080-1913

Share

Linkedin Twitter © CYTOMX INC | CYTOMX, our corporate logo, IHZ, and PROBODY are trademarks of CytomX Therapeutics, Inc. All other brands and trademarks referenced herein are the property of their respective owners.

About
Probody Therapeutics
Pipeline
Partners
- Opportunities
- Current Partners
Investors & News
Culture & Careers
Home
- Terms of Use
- Privacy Policy